Bachert C, Hellings PW, Mullol J, et al. - Given the negative impact of chronic rhinosinusitis with nasal polyposis (CRSwNP) on health-related quality of life (HRQoL) and a significant improvement reported in endoscopic, radiographic, and clinical endpoints and patient-reported outcomes after treatment with dupilumab added to mometasone furoate in patients with CRSwNP refractory to intranasal corticosteroids (INCS) in a previous randomized clinical trial, researchers studied the influence of dupilumab on HRQoL and productivity by utilizing secondary outcome data from this trial. The patients were randomly assigned to start subcutaneous dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks [n = 30], or matched placebo [n = 30]), after a 4-week mometasone furoate nasal spray run-in. According to the findings, reduction in disease severity, significant improvement in HRQoL and improved productivity were achieved with the addition of dupilumab to the treatment of adults with CRSwNP refractory to treatment with INCS alone.